This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Congenital dysfibrinogenemia이상피브리노젠혈증(선천성) (선천성이상피브리노겐혈증)

Contents and key points
ItemDetails
A. Classification codesICD-10: D68.2 | Special Copayment Reduction: V009 (rare disease)
B. SynonymsCongenital dysfibrinogenemia, Dysfibrinogenemia, Fibrinogen structural abnormality, Qualitative fibrinogen disorder, functional fibrinogen deficiency
C. Adult onsetHigh — when asymptomatic, found incidentally on testing in adulthood; the thrombotic type presents in adulthood as DVT/PE; the bleeding type is often found after pregnancy or surgery.
1. HistoryFirst report of Fibrinogen Zürich by Beck et al. in 1958. More than 400 variants reported. Overview of the Fibrinogen Mutation Database.
2. CausesVariants in the FGA, FGB, and FGG genes (4q28); usually autosomal dominant; most common variants: Aα Arg16His, Bβ Arg14Cys, γ Arg275His.
3. GeneticsFGA, FGB, FGG gene cluster at 4q28; fibrinogen triple-pair (hexamer) structure; most are heterozygous dominant variants; homozygous and compound heterozygous cases are rare and severe.
4. EpidemiologyPrevalence difficult to estimate; reporting bias exists; because the asymptomatic type is the most common, some experts estimate the actual prevalence at about 1/1,000–3,000.
5. PathophysiologyImpaired fibrinogen polymerization, abnormal thrombin cleavage, delayed FPB release, abnormal fibrin network structure; in the thrombotic type, formation of abnormal structures resistant to fibrinolysis.
6. SymptomsAsymptomatic (about 55%), bleeding type (about 25%), thrombotic type (about 20%), mixed type (rare); diversity of clinical phenotype is a key feature.
7. SignsProlonged TT and reptilase time; reduced fibrinogen activity (Clauss method), normal or slightly reduced fibrinogen antigen; PT and APTT normal or mildly prolonged.
8. ScreeningIncidental finding of prolonged TT; checking the fibrinogen antigen/activity ratio in young patients with unexplained thrombosis; women with recurrent miscarriage; family testing.
9. DiagnosisRatio of Clauss fibrinogen vs. antigen (or PT-derived fibrinogen) → TT and reptilase time → fibrin polymerization tests → FGA, FGB, FGG gene analysis.
10. TreatmentPhenotype-tailored treatment: bleeding type—fibrinogen concentrate, cryoprecipitate; thrombotic type—anticoagulation; asymptomatic type—no treatment needed; pregnancy management.
11. PrognosisVaries by phenotype; normal life in the asymptomatic type; risk of recurrence in the thrombotic type; renal amyloidosis complications with some variants (Aα Arg16His, etc.).
12. PreventionLong-term anticoagulation for the thrombotic type; preventive management during pregnancy; genetic counseling; management of thrombotic risk factors in asymptomatic patients.
13. ReferencesBeck EA et al. 1965 report of Fibrinogen Zürich and more than 11 other key references.

1. History

The beginning of fibrinogen research and the establishment of the concept of dysfibrinogenemia

Fibrinogen has been studied as the final substrate of blood coagulation since the mid-19th century. In 1859, Denis of Britain first isolated fibrinogen from plasma, and as research on the coagulation cascade progressed, the mechanism by which thrombin converts fibrinogen into fibrin was established in the mid-20th century. In 1958, Ernst Arnold Beck and colleagues in Zürich, Switzerland, found that in a patient with a bleeding tendency the thrombin time (TT) was markedly prolonged but fibrinogen antigen (immunological measurement) was normal, and named this Fibrinogen Zürich. This discovery first established the concept of a state in which the quantity of fibrinogen is normal but it is functionally abnormal, that is, the concept of dysfibrinogenemia. As similar patients were subsequently reported around the world, a tradition arose of naming each variant after the place of discovery or the patient (Fibrinogen Paris, Fibrinogen Detroit, Fibrinogen Oslo, etc.).

The Fibrinogen Mutation Database and more than 400 variants

One important milestone in dysfibrinogenemia research is the construction of a database that systematically collects and classifies variants. The Fibrinogen Mutation Database (of the Leiden Open Variation Database family), built from the 1990s, now contains more than 400 FGA, FGB, and FGG gene variants, with each variant's fibrinogen name, nucleotide variant, protein variant, clinical phenotype (asymptomatic, bleeding, thrombotic, mixed), and structural-functional effects compiled. This database has become a key resource for interpreting clinical genetic analysis results. Notably, the same variant may have different clinical phenotypes, and conversely the same phenotype (e.g., thrombotic type) may arise from completely different variants. This diversity makes dysfibrinogenemia one of the most complex coagulation disorders to understand clinically.

Dysfibrinogenemia in the molecular era: structure-function studies

Since the 1980s, as elucidation of the tertiary structure of fibrinogen by X-ray crystallography and cryo-EM advanced, molecular understanding of which step of fibrin polymerization specific variants impair developed greatly. Arg16 at the N-terminus of the fibrinogen A-alpha chain is the site where thrombin cleaves fibrinopeptide A (FPA), and the Arg16His variant at this site was confirmed as one of the most common dysfibrinogen variants. It was also shown that variants located at the polymerization site of the beta chain and at the D fragment exchange site (D:D interface) of the gamma chain each cause different kinds of fibrin polymerization impairment. This molecular knowledge became the basis for structurally explaining the bleeding and thrombotic types of dysfibrinogens and began to be used to predict the clinical course of specific variants.

Development of a clinical classification system

The clinical classification of dysfibrinogenemia has evolved over time. Initially, a simple dichotomy into bleeding and thrombotic types was used, but as later studies revealed that many patients are asymptomatic, a four-category system was established: ① asymptomatic type, ② bleeding type, ③ thrombotic type, and ④ combined bleeding + thrombotic type. In addition, according to fibrinogen antigen levels, it is divided into pure dysfibrinogenemia, with normal fibrinogen levels, and hypodysfibrinogenemia, in which fibrinogen antigen is also reduced. In this combined form, quantitative deficiency and qualitative abnormality of fibrinogen overlap and may show a more severe clinical phenotype. In the currently used ICD-10 classification (D68.2) and the Korean rare disease Special Copayment Reduction system, congenital dysfibrinogenemia is included in the category of other coagulation factor deficiencies.


2. Causes

The fibrinogen gene cluster: FGA, FGB, FGG

Congenital dysfibrinogenemia is caused by pathogenic variants in one or more of the three genes that encode the three chains of fibrinogen—A-alpha (Aα), B-beta (Bβ), and gamma (γ). The three genes, FGA (fibrinogen alpha chain, long arm of chromosome 4, 4q28), FGB (fibrinogen beta chain, 4q28), and FGG (fibrinogen gamma chain, 4q28), are all clustered in the same gene cluster on chromosome 4 (spanning about 100 kb). These three genes are expressed independently in hepatocytes, and each chain is assembled in the endoplasmic reticulum (ER) and then secreted as a hexameric fibrinogen molecule consisting of two A-alpha chains, two B-beta chains, and two gamma chains. Most dysfibrinogenemia variants express a clinical phenotype in the heterozygous state in an autosomal dominant manner, but some mild variants are asymptomatic in the heterozygous state and cause symptoms only when homozygous.

The most common variants: Aα Arg16His and fibrinopeptide cleavage site variants

The most frequently reported dysfibrinogenemia variant is the c.47G>A variant, i.e., Aα Arg16His (Fibrinogen Aarhus) in exon 2 of the FGA gene. Because Arg16 is exactly the site where thrombin cleaves fibrinopeptide A (FPA), the Arg16His variant markedly delays and reduces thrombin-mediated FPA release, interfering with fibrin polymerization. This variant is mainly associated with the bleeding or mixed type. The second most common class is variants around the fibrinopeptide B (FPB) cleavage site of the Bβ chain, typified by Bβ Arg14Cys. Among gamma chain variants, γ Arg275His and γ Arg275Cys are most strongly associated with thrombotic dysfibrinogenemia; they alter the D:D interface structure of the fibrin D fragment, forming fibrin clots that are abnormally dense and resistant to plasmin degradation.

Relationship between variant location and clinical phenotype

In dysfibrinogenemia, there is some structure-function correlation between variant location and clinical phenotype, but phenotypic diversity exists even for the same variant, so complete prediction is impossible. To summarize general trends, variants at thrombin cleavage sites (Aα Arg16, Bβ Arg14) and around the fibrin polymerization hole (including Aα Gly17-Pro18 of hole A) are mainly associated with the bleeding type. Variants at the D:D interface of the gamma chain D fragment (γ Arg275, γ Asp364) or in the gamma chain polymerization pocket (including hole B) are mainly associated with the thrombotic type. Variants in the repeat sequences of the Aα chain C-terminal region (αC domain) can cause various phenotypes through changes in fibrinogen plasma half-life or abnormal polymerization rates. In hypodysfibrinogenemia, where fibrinogen is secreted at low levels, the bleeding type appears more commonly.

Aα chain variants and renal amyloidosis

As a special form of dysfibrinogenemia, specific variants in the C-terminal region of the Aα chain (αC domain) are known to cause fibrinogen Aα-chain renal amyloidosis (AFib). These variants are diverse, mainly including fibrinogen Glu526Val (Fibrinogen Lima), Arg554Leu (Fibrinogen Appii), Gly558Val, Trp546Leu, Ile538Asn, and Leu571Pro, and are inherited in a heterozygous dominant manner. Clinically, progressive renal function decline and proteinuria develop from middle age, and renal biopsy shows amyloid deposits positive on Congo red staining. These variants cause abnormal folding of the fibrinogen protein so that the αC domain has an unstable structure, forming amyloid fibrils in the renal glomeruli. In AFib patients, renal failure rather than bleeding or thrombosis is the main clinical problem, so this special phenotype should be recognized and considered in the differential diagnosis.


3. Genetics

Genomic structure of the fibrinogen gene cluster

The FGA, FGB, and FGG genes form a gene cluster densely located within a span of about 100 kb on the long arm of chromosome 4 at 4q28. The FGA gene (about 22 kb, 6 exons) encodes the 610 amino acids of the mature Aα chain, the FGB gene (about 11 kb, 8 exons) encodes the 461 amino acids of the mature Bβ chain, and the FGG gene (about 8 kb, 10 exons) encodes the 411 amino acids of the mature γ chain (major isoform, FGG-H, 407 amino acids). Fibrinogen is a hexamer (M.W. about 340 kDa, (AαBβγ)₂) in which these three chains are combined in a 2:2:2 ratio, and it is synthesized and secreted by the liver. The normal plasma fibrinogen concentration is about 1.5~4.0 g/L (or 150~400 mg/dL), and as an acute phase reactant it rises markedly during infection, trauma, surgery, and pregnancy. Because this physiological rise also occurs in patients with dysfibrinogenemia, it must be considered that results may appear normal when testing is performed while the acute phase response is activated.

Autosomal dominance and predominance of heterozygous variants

The reason the inheritance of dysfibrinogenemia is mostly autosomal dominant is that, with heterozygous variants, the variant fibrinogen chain is assembled together with the normal chain, raising the proportion of dysfunctional fibrinogen molecules (dominant-negative effect). Because fibrinogen has a hexamer structure, any molecule containing even one variant chain has reduced overall function. Because variant and normal chains combine randomly in heterozygotes, theoretically about 75% of all fibrinogen molecules contain at least one variant chain. This is why a clinical phenotype is expressed with a heterozygous variant alone. In contrast, homozygous or compound heterozygous variants are much rarer; in these cases variant fibrinogen is present at 100% or a higher proportion, usually producing a more severe clinical phenotype.

Two gamma-chain isoforms and clinical relevance

The FGG gene produces two isoforms through alternative splicing. The major isoform, the γA chain (407 amino acids), accounts for about 85~90% of total plasma fibrinogen, and the minor isoform, the γ' chain (407+20 amino acid C-terminal extension), accounts for about 10~15%. γ' fibrinogen contains a thrombin-binding site at its C-terminus and has an antithrombin function that sequesters thrombin, and its clot structure tends to have thinner fibers than γA fibrinogen. Studies suggest that changes in the γ' fibrinogen ratio are associated with cardiovascular risk, but clinical application remains limited. Whether a dysfibrinogenemia variant is located in the γA or γ' chain may affect the clinical phenotype, adding to the genetic complexity of dysfibrinogenemia.

Fibrinogen polymorphisms and association with clinical outcomes

Among FGA gene polymorphisms, one that has been clinically studied is the α-chain Thr312Ala (c.935C>G) polymorphism. There are conflicting results, with some studies reporting that fibrinogen carrying the Ala variant forms a fibrin network of thicker fibers with faster fibrinolysis and others reporting greater resistance. Epidemiologically, associations of the Ala variant with myocardial infarction and pulmonary embolism risk have been studied, but without consistent conclusions. The 3'-UTR polymorphism of the FGG gene (10034C>T) is known to affect the γ'/γA ratio. These polymorphisms must be distinguished from pathogenic variants, and when interpreting genetic analysis results, each variant must be carefully evaluated as to whether it is a pathogenic variant actually causing dysfibrinogenemia or a polymorphism of unclear clinical significance.


4. General epidemiology

Difficulty in estimating prevalence

The exact prevalence of congenital dysfibrinogenemia is difficult to determine. This is mainly because the most common clinical form of the disease, the asymptomatic form, accounts for about 55% of all patients, so most go undiagnosed. Patients are tested only when active bleeding or a thrombotic event occurs, and in many cases the abnormality is found incidentally in that process or diagnosed through family testing. Some experts estimate the prevalence of individuals showing TT prolongation or an abnormal fibrinogen antigen/activity ratio at about 1/1,000~3,000 of the general population, but this is not an officially validated figure. The World Federation of Hemophilia report lists congenital fibrinogen disorders (dysfibrinogenemia and afibrinogenemia combined) at a prevalence of about 1 per million, but this is likely an underestimate counted mainly among patients with severe symptoms.

Distribution by clinical phenotype

According to systematic reviews of the clinical phenotype distribution of patients with dysfibrinogenemia (Miesbach 2010 and other literature combined), among reported patients the asymptomatic form is estimated at about 55%, the bleeding form about 25%, the thrombotic form about 20%, and the combined bleeding+thrombotic form 1~2%. However, these figures substantially reflect reporting bias, as diagnosis is made in symptomatic patients, so in a true population-based distribution the proportion of the asymptomatic form is estimated to be much higher. Differences in clinical phenotype by sex have also been reported: the thrombotic form is somewhat more common in men, and the bleeding form (especially pregnancy-related bleeding) tends to be more prominent in women. Age of onset differs by phenotype; the thrombotic form occurs mainly in adulthood (20s~50s), and the bleeding form varies from childhood to adulthood.

Geographic distribution and familial clustering

Dysfibrinogenemia is not concentrated in any particular ethnic group and is distributed worldwide; because it is autosomal dominant, familial clustering is high. When one patient is diagnosed, the same variant may be found in about 50% of first-degree parents and children. For some variants (e.g., certain Fibrinogen Detroit and Fibrinogen New York kindreds), family studies have traced the same variant across several generations, illustrating the characteristics of autosomal dominant inheritance well. In Korea, there is no systematic dysfibrinogenemia registry, so domestic prevalence data are unclear, but clinical experience indicates that cases of unexplained TT prolongation or fibrinogen activity/antigen discrepancy are not uncommonly found in Korean clinical laboratories.

Thrombotic dysfibrinogenemia: proportion among young patients with thrombosis

Studies have evaluated the proportion of dysfibrinogenemia in young patients with unexplained venous thromboembolism (mainly deep vein thrombosis, DVT, or pulmonary embolism, PE). The frequency of fibrinogen dysfunction found in young patients with thrombosis is variably reported at about 0.5~5%, because test methods and inclusion criteria differ between studies. In particular, the proportion of dysfibrinogenemia becomes relatively higher in patients in whom more common thrombophilias, such as antiphospholipid antibody syndrome, FV Leiden, and prothrombin G20210A, have been excluded. Dysfibrinogenemia is also not uncommonly found in studies of women with recurrent miscarriage, suggesting that fibrinogen function plays an important role in placental implantation and maintenance. These clinical contexts provide the clinical significance of screening for dysfibrinogenemia.


5. Pathophysiology

Normal fibrinogen-to-fibrin conversion

To understand the pathophysiology of dysfibrinogenemia, the normal conversion of fibrinogen to fibrin must first be understood. Fibrinogen circulating in plasma is converted sequentially by thrombin. First, thrombin cleaves the Arg16-Gly17 bond of the Aα chain, releasing fibrinopeptide A (FPA) and exposing the A polymerization site (knob A) of the fibrin monomer. Thrombin then cleaves the Arg14-Gly15 bond of the Bβ chain, releasing fibrinopeptide B (FPB) and also exposing the B polymerization site (knob B). The exposed knob A and knob B bind noncovalently to hole a (γ-chain D fragment) and hole b (β-chain D fragment) of adjacent fibrin molecules, respectively, producing half-staggered overlap polymerization. This series of polymerization steps forms 2D fibrin protofibrils, which grow into thick fibrin fibers through lateral aggregation.

Mechanism of impaired fibrin polymerization with dysfibrinogens

In dysfibrinogenemia, fibrin polymerization is impaired at various steps depending on the variant location. With thrombin cleavage site variants (Aα Arg16, Bβ Arg14), the rate at which thrombin cleaves fibrinopeptides is greatly reduced, delaying exposure of knob A or knob B and making fibrin monomer formation slow or incomplete. In this case, the characteristic finding of markedly prolonged thrombin time (TT) appears. With polymerization site or D:D interface variants (γ Arg275, γ Asp364, etc.), fibrinopeptide cleavage is normal, but D:D contact between the D fragments of fibrin monomers occurs abnormally, changing fibrin fiber structure (thickness, branching frequency, pore size). In thrombotic variants, the fibrin network formed as a result of these structural changes becomes abnormally resistant to fibrinolysis by plasmin, so once a clot forms it tends to persist without dissolving.

Mechanism of the bleeding form: insufficient fibrin formation or structural fragility

There are two main mechanisms of bleeding in bleeding-type dysfibrinogenemia. First, in variants with greatly reduced thrombin cleavage rates (mainly Aα Arg16His, Bβ Arg14Cys, etc.), fibrin monomer formation itself is slow or incomplete, so a sufficient fibrin clot does not form. In this case, standard coagulation tests (TT, PT, APTT) may be prolonged, reflecting the reduction in functional fibrinogen. Second, in some variants fibrin monomer polymerization occurs, but the fibrin network formed is structurally fragile (e.g., reduced thickness, reduced lateral association) and is easily broken down by mechanical stress or fibrinolysis. In hypodysfibrinogenemia, quantitative fibrinogen deficiency is superimposed, resulting in a more severe bleeding tendency.

Mechanism of the thrombotic form: fibrinolysis-resistant fibrin network

The molecular mechanism of thrombosis in thrombotic dysfibrinogenemia is mainly structural change of the fibrin network and the resulting increase in resistance to fibrinolysis. D:D interface variants of the gamma-chain D fragment (e.g., γ Arg275His, γ Arg275Cys) alter the D:D binding structure of fibrin protofibrils, forming a fibrin network of denser, thinner fibers. This structure limits plasmin access, reducing the rate of fibrinolysis. In addition, some variants may alter the pattern of α-chain cross-linking by FXIII or increase fibrin binding of α2-antiplasmin, acting to strengthen plasmin inhibition. As a result, in thrombotic dysfibrinogenemia, once a clot forms it is not adequately removed by the endogenous fibrinolytic system and persists, increasing the risk of deep vein thrombosis and pulmonary embolism in the venous system and stroke and myocardial infarction in the arterial system.


6. Symptoms

Asymptomatic form: clinical significance of incidental findings

The most common clinical form of dysfibrinogenemia is asymptomatic, accounting for about 55% of reported patients. These patients live normally without knowing they have dysfibrinogenemia, until TT prolongation or an abnormal fibrinogen activity/antigen ratio is found incidentally on routine preoperative coagulation testing, or it is identified during family testing of a family member diagnosed with dysfibrinogenemia. In asymptomatic patients, the risk of bleeding or thrombosis is similar to or slightly higher than in the general population, and most can live normally without specific treatment. However, asymptomatic patients may also experience unexpected bleeding in hemostatic stress situations such as surgery, delivery, and trauma, and the possibility of future thrombotic events cannot be completely ruled out, so management of thrombotic risk factors is recommended.

Clinical features of the bleeding form

In bleeding-type dysfibrinogenemia, bleeding of various sites and types can occur. Delayed bleeding after surgery or procedures shows a pattern in which hemostasis initially appears to be achieved, but rebleeding recurs within hours, reflecting the mechanism by which an unstable fibrin clot is broken down by fibrinolysis. Such delayed bleeding is particularly problematic after oral and nasopharyngeal surgery (tooth extraction, tonsillectomy), general surgery, and urologic and gynecologic surgery. Common spontaneous bleeding includes recurrent nosebleeds, gum bleeding, menorrhagia, and bruising (easy bruising hematomas); muscle hematomas and joint bleeding are less common than in hemophilia A and B but can occur. In women, menorrhagia and recurrent miscarriage are often the main symptoms, so a common path is to visit obstetrics and gynecology first and reach the diagnosis through fibrinogen testing.

Clinical features of the thrombotic form

In thrombotic dysfibrinogenemia, venous thromboembolism mainly occurs, often first presenting at a young age (20s~40s) as unexplained deep vein thrombosis (DVT) or pulmonary embolism (PE). The most common site of thrombosis is the deep veins of the lower extremities, but thrombosis can also occur at atypical sites such as the upper extremity veins, splanchnic veins (hepatic and portal veins), and cerebral venous sinuses. Arterial thromboembolism (ischemic stroke, myocardial infarction) is less common than venous thrombosis but has been reported with some variants. Clots initially appear to respond to anticoagulant treatment and resorb, but the recurrence rate tends to be high when treatment is stopped. The risk of presentation increases when thrombotic risk factors (prolonged immobility, surgery, obesity, oral contraceptives, pregnancy) are present.

Combined form and pregnancy-related symptoms

The combined form of dysfibrinogenemia, in which bleeding and thrombosis occur simultaneously or alternately, is rare but clinically the most difficult to manage. When both postoperative bleeding and venous thrombosis occur in the same patient, a dilemma arises in which fibrinogen replacement to control bleeding increases thrombotic risk. Regarding pregnancy, women with dysfibrinogenemia have increased recurrent miscarriage, placental abruption, and excessive bleeding at delivery. This is because qualitative abnormality of the fibrin matrix at the placental implantation site interferes with placental vascularization and maintenance of implantation. Because fibrinogen levels rise markedly and physiologically during pregnancy (normal third trimester: 4~6 g/L), fibrinogen antigen may appear high during pregnancy even in patients with dysfibrinogenemia, but function (Clauss method) may still be relatively low.


7. Signs

Prolongation of TT and reptilase time

The most characteristic coagulation test finding of dysfibrinogenemia is simultaneous prolongation of thrombin time (TT) and reptilase time. TT measures the time for a fibrin clot to form after exogenous thrombin is added to the patient's plasma, with a normal range of 14~21 seconds (varies by reagent). In dysfibrinogenemia, TT is prolonged because of the abnormal thrombin reactivity of the variant fibrinogen. Reptilase time is a test that uses snake venom (batroxobin, derived from Bothrops atrox) instead of thrombin to selectively cleave only FPA from fibrinogen. TT is prolonged by heparin but reptilase time is unaffected by heparin, so comparing the results of the two tests is used to distinguish TT prolongation due to heparin contamination from TT prolongation due to a fibrinogen abnormality. Dysfibrinogenemia is characterized by prolongation of both tests, whereas with heparin contamination only TT is prolonged and reptilase time is normal.

Abnormal fibrinogen antigen/activity ratio

The key test finding for diagnosing dysfibrinogenemia is a discrepancy between fibrinogen function (activity, Clauss method) and fibrinogen antigen (immunoturbidimetry or ELISA). The Clauss method measures the functional activity of fibrinogen based on thrombin time and is markedly reduced in dysfibrinogenemia. Fibrinogen antigen measurement measures the total amount of fibrinogen protein and is therefore normal or slightly reduced in dysfibrinogenemia. Thus, in dysfibrinogenemia the Clauss activity/antigen ratio is markedly lower than normal (about 1.0) (usually below 0.7). A ratio of 0.5 or less is a strong indicator of dysfibrinogenemia. However, PT-based fibrinogen measurement (a method extrapolated from PT results instead of the Clauss method) is also used in some laboratories, and this method may give higher values than the Clauss method in dysfibrinogenemia, so a fibrinogen abnormality may be missed. Functional fibrinogen must be measured by the Clauss method.

Mild changes in PT and APTT

In dysfibrinogenemia, PT and APTT are mostly normal or mildly prolonged. Because PT measures the time for the final fibrin clot to be formed by thrombin under conditions in which the TF pathway is fully activated, PT may also be prolonged when fibrinogen function is markedly reduced. However, in most patients with dysfibrinogenemia, residual fibrinogen function is maintained to some degree, so PT prolongation is often mild or absent. APTT is even less affected. Platelet count and bleeding time (BT or PFA-100) are generally normal. If fibrinogen is markedly low (hypodysfibrinogenemia), PT and APTT may be more clearly prolonged, and in this case differentiation from afibrinogenemia or hypofibrinogenemia is needed.

Fibrin polymerization assay

For more precise characterization of the abnormality, a fibrin polymerization assay can be performed. This test adds thrombin (±Ca²⁺) to patient plasma or purified fibrinogen and tracks changes in turbidity over time by absorbance at 340 nm. Normal fibrinogen shows a typical pattern of a sigmoid growth curve after the onset of polymerization, reaching maximum turbidity. In dysfibrinogenemia, various abnormal findings can appear, such as delayed fibrinopeptide release (prolonged lag phase), reduced polymerization rate (reduced slope of increase), reduced maximum turbidity, and abnormal curve shapes (atypical sigmoid curve). This assay is useful for characterizing the structural abnormalities of the bleeding and thrombotic forms. In addition, when combined with a fibrin clot lysis assay, resistance to fibrinolysis (increased in the thrombotic form) can be measured directly.


8. Screening

Differential approach to a finding of prolonged TT

The most important clinical starting point in screening for dysfibrinogenemia is the incidental finding of prolonged thrombin time (TT). Because TT prolongation has several causes, systematic differentiation is needed. The most common cause is heparin contamination of the specimen (introduced when the specimen is drawn through an infusion line), which is easily distinguished with reptilase time (heparin: TT prolonged, reptilase time normal vs. dysfibrinogenemia: both TT and reptilase time prolonged). Other causes of TT prolongation include use of direct thrombin inhibitors (argatroban, dabigatran, etc.), reduced fibrinogen (hypofibrinogenemia, disseminated intravascular coagulation), increased fibrin/fibrinogen degradation products (FDP) (systemic fibrinolysis, DIC), and monoclonal gammopathy (abnormal immunoglobulins in multiple myeloma inhibiting thrombin action). Fibrinogen quantification (Clauss method) and antigen measurement are performed together to pinpoint dysfibrinogenemia.

Screening in young patients with thrombosis

When unexplained venous thromboembolism occurs in a young patient aged 50 or younger, it is recommended to include fibrinogen function and antigen tests as part of the hereditary thrombophilia evaluation panel. Even if standard thrombophilia tests (FV Leiden, prothrombin G20210A, protein C, protein S, antithrombin, antiphospholipid antibodies) are all negative, thrombotic dysfibrinogenemia may be the cause, so adding a fibrinogen activity/antigen ratio test increases the completeness of the differential diagnosis. If an abnormal ratio is found on screening, it is confirmed with TT, reptilase time, and fibrin polymerization assay, and the variant is identified by genetic analysis. Confirming an autosomal dominant inheritance pattern through family testing increases diagnostic confidence.

Screening in recurrent miscarriage and pregnancy complications

In women with a history of two or more consecutive early pregnancy losses, placental abruption during pregnancy, or postpartum hemorrhage, it is recommended to include dysfibrinogenemia in the differential diagnosis. Fibrinogen activity (Clauss method) and antigen are measured and the ratio is calculated. Because fibrinogen rises markedly and physiologically during pregnancy, values measured before pregnancy or after postpartum recovery are more reliable than values measured during pregnancy. It is efficient to evaluate other common causes of recurrent miscarriage, such as antiphospholipid antibody syndrome, uterine anatomical abnormalities, and chromosomal abnormalities, first or simultaneously, and then to check for dysfibrinogenemia. If dysfibrinogenemia is confirmed during pregnancy, the phenotype (bleeding vs. thrombotic) is determined to establish a pregnancy management plan.

Preoperative screening and family testing

For first-degree relatives (parents, children, siblings) of a patient diagnosed with dysfibrinogenemia, fibrinogen activity/antigen ratio measurement and TT and reptilase time testing are recommended. Because inheritance is autosomal dominant, about 50% of first-degree relatives may carry the same variant. If an abnormality is found on family testing, confirmatory genetic testing is performed, and a history of bleeding and thrombosis is taken to evaluate the clinical phenotype. In patients with dysfibrinogenemia scheduled for surgery, fibrinogen activity is measured preoperatively to confirm the baseline level, and for the bleeding form a plan is made to prepare fibrinogen concentrate during surgery. For patients with the thrombotic form, an anticoagulation strategy to prevent postoperative venous thrombosis must also be planned in advance.


9. Diagnosis

Diagnostic algorithm: from prolonged TT to genetic confirmation

The stepwise approach to a definitive diagnosis of dysfibrinogenemia is as follows. Step 1: Finding of prolonged TT (or an abnormal fibrinogen activity/antigen ratio). Step 2: Perform reptilase time to exclude heparin contamination (if reptilase time is normal, heparin is the cause; if prolonged, it points toward a fibrinogen abnormality). Step 3: Simultaneously measure fibrinogen Clauss activity (functional) and immunoturbidimetric antigen (quantitative) and calculate the ratio (activity/antigen); a ratio <0.7 suggests dysfibrinogenemia, and <0.5 strongly suggests it. Step 4: Characterize the polymerization abnormality with a fibrin polymerization assay (turbidity assay). Step 5: Confirm abnormal molecular weight or abnormal bands of the variant chain by 2D electrophoresis of fibrinogen (SDS-PAGE, Western blot). Step 6: Identify the pathogenic variant by FGA, FGB, and FGG gene analysis (Sanger sequencing or NGS panel) for a definitive diagnosis. Check the clinical significance of the variant against the Fibrinogen Mutation Database.

Clauss method vs. PT-derived fibrinogen measurement

In diagnosing dysfibrinogenemia, it is important to understand the difference between Clauss and PT-derived fibrinogen measurements. The Clauss method quantifies functional fibrinogen by directly measuring fibrin clot formation time with excess thrombin, so it gives markedly low values in dysfibrinogenemia. PT-derived fibrinogen (Fibrinogen derived from PT) is a method that estimates fibrinogen using the turbidity change generated during PT measurement; because the test conditions differ from the Clauss method, it gives higher values than the Clauss method with some dysfibrinogenemia variants and the diagnosis may be missed. Therefore, when dysfibrinogenemia is suspected, functional fibrinogen must be measured by the Clauss method, and dysfibrinogenemia cannot be excluded just because PT-derived fibrinogen is not low.

FGA, FGB, and FGG gene analysis

Genetic analysis for the definitive diagnosis of dysfibrinogenemia analyzes the entire coding regions and exon-intron boundaries of the FGA (6 exons), FGB (8 exons), and FGG (10 exons) genes. Sanger sequencing analyzes each gene sequentially, and when a specific variant is strongly suspected based on the clinical phenotype or test findings, the relevant gene can be analyzed first. Using an NGS-based rare hematological disorder panel, the three genes can be analyzed simultaneously, shortening the time. After variant identification, the pathogenicity classification is checked in recognized databases such as the Fibrinogen Mutation Database and ClinVar, and the variant is classified as Pathogenic/Likely Pathogenic/VUS (uncertain significance)/Benign according to ACMG/AMP criteria. In family testing, the patient's variant site is specifically analyzed to determine carrier status.

Phenotype classification and clinical decisions

After dysfibrinogenemia is confirmed, classifying the clinical phenotype (bleeding, thrombotic, asymptomatic, combined) is essential for planning future management. Phenotype classification is made by combining three types of information: ① history-taking of the patient's past bleeding and thrombosis (including the ISTH-BAT bleeding assessment score), ② the clinical phenotypes of family members, and ③ the phenotype listed in the Fibrinogen Mutation Database for the identified variant. However, because there is phenotypic diversity even with the same variant, the phenotype cannot be fully predicted from the variant alone, and the individual patient's clinical course is the most important basis for judgment. The treatment direction (conservative vs. fibrinogen replacement vs. anticoagulation) is determined according to phenotype classification, and this classification may be reassessed over time to reflect new clinical events.


10. Treatment

Principles of phenotype-tailored treatment

There is no single approach to treating dysfibrinogenemia that applies uniformly to all patients; the principle is individualized phenotype-tailored therapy according to clinical phenotype. Most asymptomatic patients need no treatment; fibrinogen replacement is key in the bleeding form, and anticoagulant treatment is key in the thrombotic form. Treatment of the combined form (bleeding+thrombosis) is the most difficult and requires individual judgment. When making treatment decisions, it is important to consult a hematologist, integrating the patient's history of past clinical events, the characteristics of the variant, and the current clinical situation (surgical preparation, pregnancy, acute thrombosis, etc.).

Bleeding form: fibrinogen concentrate and cryoprecipitate

For treatment of acute bleeding or preoperative prophylaxis in bleeding-type dysfibrinogenemia, fibrinogen concentrate or cryoprecipitate is used to raise the plasma (functional) fibrinogen level. Commercially available human plasma-derived fibrinogen concentrates (e.g., Haemocomplettan®/RiaSTAP®, CSL Behring) have undergone viral inactivation, and a single dose is calculated as the amount needed to raise plasma fibrinogen to a target level of about 1.5~2.0 g/L or higher (usually 25~50 mg/kg). Cryoprecipitate contains FXIII, vWF, and FVIII in addition to fibrinogen, so it is advantageous when replacement of these factors is also needed. Tranexamic acid can be used as an adjunct to fibrinogen replacement to inhibit fibrinolysis and increase the stability of the fibrin clot. In dysfibrinogenemia, the target fibrinogen level for treatment is generally set at 1.5~2.5 g/L or higher depending on the severity of bleeding or surgery.

Thrombotic form: anticoagulant treatment

When a thrombotic event occurs in thrombotic dysfibrinogenemia, anticoagulant treatment is given in line with the treatment of venous thromboembolism in the general population. In the acute phase, low-molecular-weight heparin (LMWH) or fondaparinux is used, followed by a switch to an oral anticoagulant (vitamin K antagonist or direct oral anticoagulant, NOAC). The duration and intensity of anticoagulation are determined by the site of thrombosis (proximal DVT, PE vs. distal DVT), recurrence, presence of provoking factors, and accompanying bleeding risk. Because the risk of recurrence is high in thrombotic dysfibrinogenemia, indefinite anticoagulation is sometimes considered, but this must be decided by balancing it against the individual patient's bleeding risk. The efficacy of NOACs in thrombosis accompanied by dysfibrinogenemia can be expected to be the same as in general VTE, but there are no dedicated clinical trial data on this.

Management during pregnancy

Pregnancy management in women with dysfibrinogenemia differs by phenotype. In the bleeding form, regular fibrinogen activity monitoring is performed during pregnancy, fibrinogen concentrate is prepared in advance for the peripartum period, and it is given immediately if bleeding increases at delivery. In the thrombotic form, anticoagulant prophylaxis (low-molecular-weight heparin) is given during pregnancy and the puerperium. Cases have been reported in which women with dysfibrinogenemia and a history of recurrent miscarriage successfully maintained pregnancy with combined low-molecular-weight heparin and fibrinogen replacement during pregnancy, but a standardized pregnancy management protocol has not yet been established, so close collaboration between hematologists and obstetrician-gynecologists is essential.


11. Prognosis

Variation in prognosis by phenotype

The prognosis of dysfibrinogenemia varies greatly by clinical phenotype. The asymptomatic form accounts for the majority of all patients, and their prognosis does not differ greatly from that of the general population. With regular follow-up, managing thrombotic risk factors and making appropriate preparations before surgery allows a normal life without long-term complications. In the bleeding form, most bleeding complications can be prevented through appropriate fibrinogen replacement during surgery, delivery, and trauma, but when diagnosis is delayed, complications due to excessive postoperative bleeding can occur. In the thrombotic form, recurrence can be prevented with appropriate anticoagulant treatment, but the risk of recurrence after stopping treatment is high, and some patients need long-term anticoagulation. Chronic complications such as post-thrombotic syndrome or pulmonary hypertension can occur after a thrombotic event.

Special prognosis with renal amyloidosis variants

In fibrinogen Aα-chain renal amyloidosis (AFib) caused by Aα-chain C-terminal variants, renal failure rather than bleeding or thrombosis is the main clinical problem. Without treatment, renal function gradually declines and progresses to end-stage renal disease (ESRD), and kidney transplantation is the most effective treatment. Because amyloid deposition can recur in the transplanted kidney after kidney transplantation, in the long term combined liver-kidney transplantation is regarded as the ideal option that simultaneously achieves treatment of the genetic cause (blocking secretion of abnormal fibrinogen from the liver) and recovery of kidney function. The prognosis of AFib depends on the degree of renal function decline before transplantation, the presence of amyloid deposition in the heart and other organs, and post-transplant management.

Pregnancy prognosis and long-term follow-up

In women with bleeding-type dysfibrinogenemia, the risk of recurrent miscarriage and delivery complications is high without pregnancy management, but successful pregnancy outcomes can be expected when appropriate preventive measures are taken under the care of a hematologist. In the thrombotic form, thrombotic risk can be lowered with low-molecular-weight heparin prophylaxis during pregnancy. Long-term follow-up of patients with dysfibrinogenemia basically includes fibrinogen activity/antigen measurement at least once a year, recording of bleeding and thrombotic events, and reassessment of phenotype. Patients receiving anticoagulant treatment for the thrombotic form need monitoring of anticoagulation intensity (INR, or anti-Xa level in the case of NOACs) and surveillance for bleeding complications. With advances in treatment technology and genetic confirmation, the prognosis of patients with dysfibrinogenemia is continuing to improve.

Quality of life and psychosocial aspects

It is important to provide sufficient explanation and counseling so that a diagnosis of dysfibrinogenemia minimizes the patient's psychological burden. In particular, asymptomatic patients should be clearly told that their condition has little clinical significance, to prevent unnecessary anxiety. When surgery is needed, patients are guided to work with a hematologist before surgery to establish a safe surgical plan. Patients with the thrombotic form on long-term anticoagulation are given specific counseling on daily activities (exercise, alcohol, diet management). Because dysfibrinogenemia is a genetic disease, the fact that it can be passed on to children and siblings is explained, while conveying that its impact on life can vary greatly by phenotype.


12. Prevention

Asymptomatic form: management of thrombotic risk factors

In patients with asymptomatic dysfibrinogenemia, specific drug prophylaxis is generally not needed. However, because the possibility of conversion to a thrombotic phenotype cannot be completely ruled out, active management of general thrombotic risk factors is recommended. This includes not smoking, weight management (keeping BMI below 25), avoiding prolonged immobility (stretching and compression stockings during air travel), choosing estrogen-free contraception instead of estrogen-containing oral contraceptives, and standard thromboprophylactic anticoagulation after high-risk surgery. Regular consultation with a hematologist to monitor for changes in clinical phenotype is also recommended.

Thrombotic form: long-term anticoagulant prophylaxis

In patients with thrombotic dysfibrinogenemia who have had one or more thrombotic events, long-term anticoagulation to prevent recurrence should be considered. The risk of recurrence is higher when the thrombosis occurred without a provoking factor (unprovoked VTE) and the stronger the thrombogenic tendency of the variant. The choice of anticoagulant is made considering the patient's bleeding risk, other diseases, pregnancy plans, and convenience of use; vitamin K antagonists (maintaining INR 2~3) or direct oral anticoagulants (NOAC) are mainly used. Before surgery, a bridging therapy strategy of temporarily interrupting anticoagulation is applied, and for surgery with high thrombotic risk, anticoagulation is resumed promptly after surgery. During pregnancy, low-molecular-weight heparin is used instead of oral anticoagulants.

Bleeding form: preoperative prevention plan

When a patient with bleeding-type dysfibrinogenemia undergoes surgery, it is essential to work with a hematologist in advance to establish a bleeding prevention plan. Fibrinogen function (Clauss activity) is measured before surgery to confirm the baseline level, and the dose of fibrinogen concentrate to prepare in advance is calculated according to the surgical bleeding risk. Fibrinogen levels are monitored during and after surgery to maintain 1.5~2.0 g/L or higher. Concomitant perioperative use of tranexamic acid can increase the stability of the fibrin clot. Even for tooth extraction or minor outpatient procedures, fibrinogen activity is checked in advance, and for high-risk procedures (sites with high fibrinolytic activity such as the oral cavity, urinary tract, and uterus), prophylactic tranexamic acid is considered.

Pregnancy management and genetic counseling

Before women with dysfibrinogenemia plan a pregnancy, genetic counseling explains the risk of transmitting the variant to children (50%) and the uncertainty in predicting the clinical phenotype in children. During pregnancy, fibrinogen activity is monitored regularly across the three trimesters, and the obstetric and hematology teams establish a delivery plan together. Regardless of the mode of delivery (vaginal delivery vs. cesarean section), fibrinogen concentrate is kept ready and given prophylactically in situations where bleeding is expected. During the high thrombotic risk period of 4~6 weeks postpartum, low-molecular-weight heparin prophylaxis is continued in patients with the thrombotic form. In newborns, measuring fibrinogen activity/antigen in cord blood or early after birth to check for deficiency is recommended as part of family testing.


13. References

  1. Beck EA, Charache P, Jackson DP. A new inherited coagulation disorder caused by an abnormal fibrinogen ('fibrinogen Baltimore'). Nature. 1965;208(5016):143-145.
  2. Hanss M, Biot F. A database for human fibrinogen variants. Ann N Y Acad Sci. 2001;936:89-90.
  3. Casini A, Blondon M, Lebreton A, et al. Natural history of patients with congenital dysfibrinogenemia. Blood. 2015;125(3):553-561.
  4. de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost. 2013;39(6):585-595.
  5. Neerman-Arbez M, de Moerloose P, Casini A. Laboratory and genetic investigation of mutations accounting for congenital fibrinogen disorders. Semin Thromb Hemost. 2016;42(4):356-365.
  6. Miesbach W, Scharrer I, Henseler A, et al. Inherited dysfibrinogenemia: clinical phenotypes associated with five different fibrinogen structure defects. Blood Coagul Fibrinolysis. 2010;21(1):35-40.
  7. Peyvandi F, Menegatti M, Palla R. Rare bleeding disorders: worldwide efforts for classification, diagnosis, and management. Semin Thromb Hemost. 2013;39(6):579-584.
  8. Undas A, Ariëns RAS. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol. 2011;31(12):e88-e99.
  9. Lim MY, Berber E, Aburiziza A, et al. Fibrinogen disorders: afibrinogenemia, hypofibrinogenemia, and dysfibrinogenemia. In: Kitchens CS et al., eds. Consultative Hemostasis and Thrombosis. 4th ed. Elsevier; 2019:133-150.
  10. Stachowiak B, Peyvandi F, Mannucci PM. Congenital fibrinogen disorders: from bleeding to thrombosis. Haemophilia. 2012;18(3):331-337.
  11. World Federation of Hemophilia. Diagnosis and Management of Rare Coagulation Disorders. WFH; 2020.
  12. Casini A, de Moerloose P. How I treat dysfibrinogenemia. Blood. 2021;138(24):2571-2581.